SCHEMBL2189267

SCHEMBL2189267

CC(C)([C@H]1CCN(c2cnc(C(F)(F)F)cn2)C(=O)C1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.45
CACNA1B Q00975 3/20 0.45
NR1I2 O75469 1/20 0.45
KDM4E B2RXH2 1/20 0.41
NR1H2 P55055 2/20 0.40
NR1H3 Q13133 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.38
HSD11B1 P28845 1/20 0.37
CNR1 P21554 1/20 0.37
CTSS P25774 1/20 0.36
HTR6 P50406 1/20 0.36
CYP2C19 P33261 2/20 0.36
POLB P06746 1/20 0.35
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA4 P22748 2/20 0.35
CA7 P43166 2/20 0.35
CA9 Q16790 2/20 0.35
TRPV1 Q8NER1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2191324 1.00 CYP3A4 (0.45) CYP3A4CACNA1BNR1I2KDM4ENR1H2
SCHEMBL7920460 0.90 CYP3A4 (0.46) CYP3A4CACNA1BNR1I2KDM4ENR1H2
SCHEMBL2189730 0.90 CYP3A4 (0.46) CYP3A4CACNA1BNR1I2KDM4ENR1H2
SCHEMBL2196073 0.90 CYP3A4 (0.46) CYP3A4CACNA1BNR1I2KDM4ENR1H2
SCHEMBL2191575 0.89 CACNA1B (0.51) CYP3A4CACNA1BNR1I2KDM4ENR1H2
SCHEMBL2188044 0.89 CACNA1B (0.51) CYP3A4CACNA1BNR1I2KDM4ENR1H2
SCHEMBL2190115 0.87 CACNA1B (0.47) CYP3A4CACNA1BNR1I2KDM4ENR1H2
SCHEMBL2189252 0.87 CACNA1B (0.44) CYP3A4CACNA1BNR1I2KDM4EL3MBTL1
SCHEMBL2189754 0.87 CYP3A4 (0.47) CYP3A4CACNA1BNR1I2KDM4EL3MBTL1
SCHEMBL2188879 0.87 CYP3A4 (0.47) CYP3A4CACNA1BNR1I2KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US claimed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D CYP3A4 939/4885CACNA1B 23/4885NR1I2 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.